Dow Jones

38,589.16

-0.15%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NYSE
Dr Reddys Laboratories Ltd (RDY)
Dr Reddys Laboratories Ltd (RDY) Noticias

RDY

Dr Reddys Laboratories (RDY)

Dr Reddys Laboratories Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:RDY

1 2 3 4 5 6 7 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
14/06/2024	08:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NYSE:RDY	Dr Reddys Laboratories Ltd
12/06/2024	16:05	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NYSE:RDY	Dr Reddys Laboratories Ltd
03/06/2024	12:05	Business Wire	Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities	NYSE:RDY	Dr Reddys Laboratories Ltd
28/05/2024	08:53	Business Wire	Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America	NYSE:RDY	Dr Reddys Laboratories Ltd
21/05/2024	09:05	Business Wire	Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK	NYSE:RDY	Dr Reddys Laboratories Ltd
21/05/2024	07:00	GlobeNewswire Inc.	Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK	NYSE:RDY	Dr Reddys Laboratories Ltd
07/05/2024	09:31	Business Wire	Dr. Reddy’s Q4 & Full Year FY24 Financial Results	NYSE:RDY	Dr Reddys Laboratories Ltd
03/05/2024	07:00	Business Wire	Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.	NYSE:RDY	Dr Reddys Laboratories Ltd
22/03/2024	06:00	GlobeNewswire Inc.	Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India	NYSE:RDY	Dr Reddys Laboratories Ltd
19/03/2024	06:00	Business Wire	Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK	NYSE:RDY	Dr Reddys Laboratories Ltd
31/01/2024	08:44	Business Wire	Dr. Reddy’s Q3 & 9M FY24 Financial Results	NYSE:RDY	Dr Reddys Laboratories Ltd
16/01/2024	07:58	Dow Jones News	Indian Dr. Reddy's in Talks to Buy Haleon's Nicotinell, Sky News Reports	NYSE:RDY	Dr Reddys Laboratories Ltd
03/01/2024	05:00	Business Wire	Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands	NYSE:RDY	Dr Reddys Laboratories Ltd
14/12/2023	06:49	Business Wire	Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index	NYSE:RDY	Dr Reddys Laboratories Ltd
06/12/2023	06:55	Dow Jones News	Coya Therapeutics Strikes Development, Commercialization Deal With Dr. Reddy's for ALS Drug	NYSE:RDY	Dr Reddys Laboratories Ltd
06/12/2023	06:00	Business Wire	Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)	NYSE:RDY	Dr Reddys Laboratories Ltd
27/10/2023	12:50	Business Wire	Dr. Reddy’s Q2 FY24 Financial Results	NYSE:RDY	Dr Reddys Laboratories Ltd
27/10/2023	10:03	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:RDY	Dr Reddys Laboratories Ltd
10/08/2023	06:00	Business Wire	Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.	NYSE:RDY	Dr Reddys Laboratories Ltd
26/07/2023	11:31	Business Wire	Dr. Reddy’s Q1 FY24 Financial Results	NYSE:RDY	Dr Reddys Laboratories Ltd
12/07/2023	09:25	Business Wire	Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA	NYSE:RDY	Dr Reddys Laboratories Ltd
23/06/2023	05:07	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NYSE:RDY	Dr Reddys Laboratories Ltd
13/06/2023	13:15	Dow Jones News	Journey Medical Up 21% on Rosacea-Drug Data	NYSE:RDY	Dr Reddys Laboratories Ltd
05/06/2023	06:00	Business Wire	Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab	NYSE:RDY	Dr Reddys Laboratories Ltd
10/05/2023	10:43	Business Wire	Dr. Reddy’s Q4 & FY23 Financial Results	NYSE:RDY	Dr Reddys Laboratories Ltd
05/05/2023	06:17	Business Wire	Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.	NYSE:RDY	Dr Reddys Laboratories Ltd
21/04/2023	06:15	Business Wire	Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.	NYSE:RDY	Dr Reddys Laboratories Ltd
20/03/2023	06:00	Business Wire	Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases	NYSE:RDY	Dr Reddys Laboratories Ltd
27/02/2023	05:00	Business Wire	Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio	NYSE:RDY	Dr Reddys Laboratories Ltd
08/02/2023	07:50	Business Wire	Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year	NYSE:RDY	Dr Reddys Laboratories Ltd